VYGR: Voyager Therapeutics, Inc.
About
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Current Value
$5.491 Year Return
Current Value
$5.491 Year Return
Key Details
Market Cap
$296.62M
P/E Ratio
7.53
1Y Stock Return
-21.08%
1Y Revenue Growth
3.40%
Dividend Yield
0.00%
Price to Book
0.9
Strategies that include VYGR
Stock's related to VYGR
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PLRX | 43.25% | $781.97M | -7.75% | 0.00% |
| ELVN | 39.99% | $1.24B | +122.89% | 0.00% |
| EDIT | 39.79% | $195.64M | -77.41% | 0.00% |
| PRTA | 39.52% | $777.00M | -55.88% | 0.00% |
| RCKT | 38.57% | $1.17B | -41.62% | 0.00% |
| RGNX | 38.43% | $454.82M | -52.01% | 0.00% |
| PGEN | 37.96% | $259.78M | -20.80% | 0.00% |
| RCUS | 37.37% | $1.31B | +2.96% | 0.00% |
| ALEC | 37.29% | $368.23M | -22.31% | 0.00% |
| ARWR | 36.91% | $2.27B | -36.88% | 0.00% |
| XNCR | 36.46% | $1.69B | +28.67% | 0.00% |
| ALLO | 36.28% | $442.41M | -22.43% | 0.00% |
| CRNX | 35.96% | $5.29B | +85.52% | 0.00% |
| CMPS | 35.27% | $304.47M | -26.45% | 0.00% |
| MNKD | 34.97% | $1.90B | +89.04% | 0.00% |
| QTRX | 34.86% | $449.80M | -51.51% | 0.00% |
| ENTA | 34.83% | $197.27M | +3.56% | 0.00% |
| DENN | 34.11% | $327.99M | -34.39% | 0.00% |
| BCRX | 34.01% | $1.55B | +39.48% | 0.00% |
| ATNM | 33.64% | $45.86M | -66.74% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PULM | -0.01% | $22.32M | +230.27% | 0.00% |
| FCN | 0.05% | $7.12B | -10.52% | 0.00% |
| ZCMD | 0.15% | $2.67M | -88.95% | 0.00% |
| OXBR | 0.20% | $19.24M | +183.49% | 0.00% |
| MNST | 0.24% | $52.50B | -2.25% | 0.00% |
| PG | 0.26% | $406.83B | +14.39% | 2.27% |
| AMED | -0.27% | $2.95B | -3.97% | 0.00% |
| FENG | 0.32% | $13.53M | +94.49% | 0.00% |
| BNED | -0.33% | $270.40M | -91.94% | 0.00% |
| DLNG | 0.34% | $156.41M | +62.21% | 0.00% |
| DT | -0.41% | $15.66B | +1.06% | 0.00% |
| TMUS | 0.47% | $274.55B | +58.87% | 0.82% |
| NATL | 0.51% | $2.26B | +36.84% | 0.00% |
| NEUE | 0.53% | $41.96M | -33.09% | 0.00% |
| AFL | 0.58% | $62.07B | +35.55% | 1.78% |
| DXYZ | -0.67% | - | - | 0.00% |
| LMT | 0.68% | $128.48B | +20.34% | 2.32% |
| NLOP | 0.73% | $459.67M | +97.90% | 0.00% |
| PSLV | 0.73% | - | - | 0.00% |
| K | 0.76% | $27.93B | +52.93% | 2.77% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HIHO | -25.93% | $8.50M | -1.53% | 6.22% |
| PM | -14.43% | $204.01B | +39.85% | 4.01% |
| CBOE | -13.83% | $22.09B | +17.17% | 1.08% |
| CME | -13.20% | $81.64B | +7.34% | 2.00% |
| TCTM | -11.42% | $7.57M | -41.30% | 0.00% |
| CYD | -9.99% | $384.48M | -0.79% | 4.00% |
| SCKT | -8.63% | $11.26M | +14.73% | 0.00% |
| FTNT | -8.43% | $72.06B | +77.50% | 0.00% |
| TKC | -7.94% | $5.96B | +38.82% | 1.32% |
| XGN | -7.51% | $69.14M | +151.28% | 0.00% |
| MCK | -6.87% | $79.75B | +37.34% | 0.41% |
| INSP | -6.70% | $5.58B | +29.21% | 0.00% |
| COR | -6.30% | $48.41B | +23.04% | 0.84% |
| NTZ | -5.98% | $47.64M | -30.80% | 0.00% |
| CHD | -4.47% | $27.50B | +19.29% | 1.01% |
| VHC | -4.36% | $18.68M | -40.78% | 0.00% |
| RSG | -3.87% | $67.03B | +33.78% | 1.01% |
| LUMO | -3.85% | $37.45M | +40.58% | 0.00% |
| MNOV | -3.77% | $98.09M | +5.26% | 0.00% |
| MASI | -3.68% | $9.05B | +82.56% | 0.00% |
ETF's related to VYGR
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 46.64% | $6.75B | 0.35% |
| RSPA | 46.25% | $272.75M | 0% |
| IBB | 46.18% | $6.64B | 0.45% |
| PBE | 44.29% | $253.13M | 0.58% |
| IWC | 43.48% | $943.89M | 0.6% |
| FBT | 41.50% | $1.13B | 0.56% |
| PTH | 41.13% | $141.72M | 0.6% |
| GNOM | 41.04% | $71.22M | 0.5% |
| IWO | 40.58% | $12.75B | 0.24% |
| XPH | 40.40% | $161.72M | 0.35% |
| BBH | 39.68% | $404.59M | 0.35% |
| VTWO | 39.51% | $12.48B | 0.1% |
| GSSC | 39.49% | $533.32M | 0.2% |
| QQA | 39.37% | $135.25M | 0% |
| IWM | 39.32% | $75.93B | 0.19% |
| FHLC | 38.63% | $2.75B | 0.084% |
| ARKG | 38.61% | $1.14B | 0.75% |
| VHT | 38.58% | $17.20B | 0.1% |
| SMMV | 38.51% | $322.61M | 0.2% |
| SLYG | 38.25% | $3.72B | 0.15% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BILZ | 0.04% | $553.02M | 0.14% |
| BSCO | -0.19% | $2.31B | 0.1% |
| TBIL | -0.34% | $4.39B | 0.15% |
| PREF | -0.51% | $1.01B | 0.55% |
| TBLL | 0.58% | $1.92B | 0.08% |
| HIGH | 0.78% | $301.36M | 0.51% |
| TPMN | -1.37% | $40.73M | 0.65% |
| PDBC | 1.40% | $4.47B | 0.59% |
| IBTE | 1.47% | $1.67B | 0.07% |
| GSG | 1.49% | $935.59M | 0.75% |
| FMF | -1.58% | $243.44M | 0.95% |
| CANE | -1.76% | $17.43M | 0.29% |
| ULST | -1.78% | $535.66M | 0.2% |
| XBIL | -2.10% | $637.84M | 0.15% |
| SGOV | 2.14% | $27.69B | 0.09% |
| EQLS | -2.36% | $8.88M | 1% |
| FLTR | 2.61% | $1.79B | 0.14% |
| KRBN | 2.90% | $243.28M | 0.85% |
| CORN | -3.09% | $61.32M | 0.2% |
| CLOI | 3.10% | $720.91M | 0.4% |
News
Yahoo
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager’s IV-delivered, CNS-penetrant TRACER capsids - LEXINGTON, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has selected a lead development candidat
SeekingAlpha
Voyager Therapeutics' promising anti-tau Alzheimerâs therapy faces long timelines. See why VYGR stock is rated Hold but remains a long-term opportunity.
Yahoo
It is hard to get excited after looking at Voyager Therapeutics' (NASDAQ:VYGR) recent performance, when its stock has...
Yahoo
Q3 2024 Voyager Therapeutics Inc Earnings Call
Yahoo
Voyager Therapeutics Inc (VYGR) reports a robust financial runway and advances in Alzheimer's research, despite challenges in clinical trials.
SeekingAlpha
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2024 Results Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsTrista Morrison - Chief...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.